Hepatitis C

In a new trial, investigators find glecaprevir and pibrentasvir is safe to treatment HCV patients who failed treatment with an NS5A inhibitor.

At the annual ACG meeting, Carlos Romero-Marrero, MD and Mohammad Alomari, MD discuss what can be done to reduce the drug use rate for high risk patients.

Roberto Simons-Linares, MD, presents new data at the annual ACG meeting on the association between hepatitis viral infections and acute pancreatitis.

In a retrospective study presented at the annual ACG meeting, investigators examine sex and ethnicity data involving linkage to care for hepatitis C virus patients.

Hepatitis C virus infections are strongly linked to type 2 diabetes, according to new research.

The FDA approves Mavyret as an 8-week treatment for all genotypes of HCV with compensated cirrhosis.

In the updated guidelines, investigators suggest direct-acting antivirals as the preferred treatment for hepatitis C viral infections in chronic kidney disease patients.

Investigators find that sofosbuvir is less effective on some HCV infections because of certain amino acid substitutions.

In a 53-patient observational study, investigators discover they can safely transplant a HCV-infected kidney into a HCV-negative recipients.

The FDA warns of liver failure in rare cases from taking Mavyret, Zepatier, and Vosevi to treat hepatitis C.

A team of investigators review global HCV infection rates in an attempt to quantify HCV-associated cardiovascular disease.

Robert G. Gish, MD, and the Global Liver Institute join up for a talk on all things hepatology.

Proof-of-concept study follows patients who receive a HCV-positive donor heart.

Investigators analyze impact of needle and syringe, hepatitis C elimination program in the country of Georgia.

Guidelines include combination of vaccines, screenings and case management to prevent hepatitis B from infecting infants.

The Gilead subsidiary will provide the authorized generic of sofosbuvir/velpatasvir for the state's at-risk patient population over 5 years.

Less than half of US adults with either HBV or HCV infection are aware of their condition, and even among those aware, few receive appropriate treatment.

Kaiser Permanente Northern California’s study shows that the pertussis vaccine weakens as time passes after a patient's most recent vaccination.

A new study debunks preceding fears that direct-acting antivirals increase the likelihood of adverse events for patients with the hepatitis C virus.

Using education, EHR alerts, and increased clinic capacity, investigators increased HCV screening of baby boomers from 10.1% to 34.6%.

Short-course, "post-exposure" direct-acting antivirals enabled successful transplantation of HCV-infected hearts and lungs to uninfected recipients.

Currently, DAAs lack FDA approval for hepatitis C treatment in children under 12 years, but pediatricians call for their approval.

A randomized trial compared cash incentives, peer support, and usual care for increasing rate of HCV treatment among HCV/HIV infected people who use drugs.

In a 47-patient study, all who received the therapy for either 8 or 16 weeks had no detected virus in their blood samples post-12 weeks, indicating cured infection.

A study of DAA treatment of HCV in the US finds high adherence and effectiveness at less cost than when the antivirals were introduced.